Literature DB >> 23886700

Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223.

Eric A Benson1, Todd C Skaar.   

Abstract

Plasma-derived microRNAs (miRNAs) are being used as biomarkers, and have been associated with human liver disease and function including fibrosis, inflammation, and drug-induced liver injury. They may also be biomarkers of the drug metabolism function of the liver. In order for plasma miRNA to function as a clinical biomarker, predictable variability is necessary during processing from whole blood to plasma. The current study evaluated the variability of miRNA in whole blood stored for 0.5, 1, 2, 4, 8, and 12 hours following the blood draw under clinical conditions (room temperature) prior to the separation of the plasma. Four healthy volunteers were recruited. Blood from all subjects was collected twice. MicroRNA-16 (miR-16) and miR-223 were evaluated because many studies have shown them to be reliably present in plasma and useful for normalization. miRNA concentrations were measured by real-time polymerase chain reaction. The coefficient of variability of the cycle threshold values for subjects for miR-223 and miR-16 ranged from ∼3.6 to 6.8% and ∼1.48 to 4.1%, respectively, over the 12-hour incubation. A second blood collection was performed to determine interday variability. The coefficient of variance from the initial blood draw compared with the final blood draw for each subject ranged from 0.42 to 7.9% for miR-16 and 1.7 to 8.3% for miR-223, indicating that these miRNAs have limited interday variability. We conclude that plasma miR-16 or miR-223 concentrations are stable in whole blood at room temperature for up to 12 hours.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23886700      PMCID: PMC3781369          DOI: 10.1124/dmd.113.052357

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

1.  Stabilization of mRNA expression in whole blood samples.

Authors:  Lynne Rainen; Uwe Oelmueller; Stewart Jurgensen; Ralf Wyrich; Cynthia Ballas; Jim Schram; Chris Herdman; Danute Bankaitis-Davis; Nancy Nicholls; David Trollinger; Victor Tryon
Journal:  Clin Chem       Date:  2002-11       Impact factor: 8.327

2.  Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver.

Authors:  Shu-Yun Zhang; Sailesh Surapureddi; Sherry Coulter; Stephen S Ferguson; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2012-06-20       Impact factor: 4.436

Review 3.  Horizontal transfer of RNAs: exosomes as mediators of intercellular communication.

Authors:  Saraswathi Ramachandran; Viswanathan Palanisamy
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-10-19       Impact factor: 9.957

4.  Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases.

Authors:  Shashi Bala; Jan Petrasek; Shiv Mundkur; Donna Catalano; Ivan Levin; Jeanine Ward; Hawau Alao; Karen Kodys; Gyongyi Szabo
Journal:  Hepatology       Date:  2012-07-26       Impact factor: 17.425

5.  Plasma microRNA profiles distinguish lethal injury in acetaminophen toxicity: a research study.

Authors:  Jeanine Ward; Shashi Bala; Jan Petrasek; Gyongyi Szabo
Journal:  World J Gastroenterol       Date:  2012-06-14       Impact factor: 5.742

6.  In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4α expression.

Authors:  Anuradha Ramamoorthy; Lang Li; Andrea Gaedigk; L DiAnne Bradford; Eric A Benson; David A Flockhart; Todd C Skaar
Journal:  Drug Metab Dispos       Date:  2012-01-09       Impact factor: 3.922

7.  Sensitive PCR-based quantitation of cell-free circulating microRNAs.

Authors:  Michelle L Hastings; Jaime Palma; Dominik M Duelli
Journal:  Methods       Date:  2012-08-03       Impact factor: 3.608

8.  Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis.

Authors:  Yu Yamaura; Miki Nakajima; Shingo Takagi; Tatsuki Fukami; Koichi Tsuneyama; Tsuyoshi Yokoi
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

9.  Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease.

Authors:  Yoshiki Murakami; Hidenori Toyoda; Toshihito Tanahashi; Junko Tanaka; Takashi Kumada; Yusuke Yoshioka; Nobuyoshi Kosaka; Takahiro Ochiya; Y-h Taguchi
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

10.  Whole blood-derived microRNA signatures in mice exposed to lipopolysaccharides.

Authors:  Ching-Hua Hsieh; Cheng-Shyuan Rau; Jonathan Chris Jeng; Yi-Chun Chen; Tsu-Hsiang Lu; Chia-Jung Wu; Yi-Chan Wu; Siou-Ling Tzeng; Johnson Chia-Shen Yang
Journal:  J Biomed Sci       Date:  2012-07-31       Impact factor: 8.410

View more
  12 in total

1.  Expression profiling analysis of the microRNA response of Cynoglossus semilaevis to Vibrio anguillarum and other stimuli.

Authors:  Guangye Gong; Zhenxia Sha; Songlin Chen; Chao Li; Hui Yan; Yadong Chen; Tianzi Wang
Journal:  Mar Biotechnol (NY)       Date:  2015-02-26       Impact factor: 3.619

2.  Improving the Patency of Jugular Vein Catheters in Sprague-Dawley Rats by Using an Antiseptic Nitrocellulose Coating.

Authors:  Thomas De Luca; Keely L Szilágyi; Katherine A Hargreaves; Kimberly S Collins; Eric A Benson
Journal:  J Am Assoc Lab Anim Sci       Date:  2018-08-03       Impact factor: 1.232

3.  Identification of Suitable Endogenous Normalizers for qRT-PCR Analysis of Plasma microRNA Expression in Essential Hypertension.

Authors:  Mohamed Hassan M Solayman; Taimour Langaee; Archanakumari Patel; Lamia El-Wakeel; Manal El-Hamamsy; Osama Badary; Julie A Johnson
Journal:  Mol Biotechnol       Date:  2016-03       Impact factor: 2.695

4.  Epigenetic regulation of ADME-related genes: focus on drug metabolism and transport.

Authors:  Xiao-bo Zhong; J Steven Leeder
Journal:  Drug Metab Dispos       Date:  2013-08-09       Impact factor: 3.922

5.  Plasma miR-940 may serve as a novel biomarker for gastric cancer.

Authors:  Xin Liu; Ava Kwong; Alan Sihoe; Kent-Man Chu
Journal:  Tumour Biol       Date:  2015-10-11

6.  Assay reproducibility in clinical studies of plasma miRNA.

Authors:  Jonathan Rice; Henry Roberts; James Burton; Jianmin Pan; Vanessa States; Shesh N Rai; Susan Galandiuk
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

7.  Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study.

Authors:  Lisa Repsold; Thandi Mqoco; Elize Wolmarans; Sandra Nkandeu; Joji Theron; Tomek Piorkowski; Peet du Toit; Dirk van Papendorp; Annie Margaretha Joubert
Journal:  Biol Res       Date:  2014-09-04       Impact factor: 5.612

8.  Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.

Authors:  Eric A Benson; Todd C Skaar; Yunlong Liu; Kenneth P Nephew; Daniela Matei
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

Review 9.  MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.

Authors:  Lisa-Maria Schanza; Maximilian Seles; Michael Stotz; Johannes Fosselteder; Georg C Hutterer; Martin Pichler; Verena Stiegelbauer
Journal:  Int J Mol Sci       Date:  2017-11-22       Impact factor: 5.923

10.  MicroRNA-200c as a prognostic and sensitivity marker for platinum chemotherapy in advanced gastric cancer.

Authors:  Min Li; Kangsheng Gu; Wei Liu; Xiaoque Xie; Xiaolu Huang
Journal:  Oncotarget       Date:  2017-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.